0000000000920294

AUTHOR

Giuseppe Perrone

showing 21 related works from this author

PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients

2012

PML regulates a wide range of pathways involved in tumorigenesis, such as apoptosis, which is also one of the main mechanisms through which oxaliplatin and fluoropyrimidine exert their antineoplastic activity. The present study aims to investigate PML expression as a predictive factor of oxaliplatin/fluoropyrimidine therapy efficacy. Seventy-four metastatic colorectal cancer patients who received oxaliplatin/floropyrimidine-based first line therapy have been included in this retrospective study. PML expression was assessed by immunohistochemistry. PML down-regulation was detected in 39 (52.7%) patients (14 complete and 25 partial PML loss). RR was significantly lower (25.6%) in patients wit…

OncologyMaleOrganoplatinum CompoundsOxaloacetatesPhysiologyColorectal cancerSettore MED/06 - Oncologia MedicavirusesClinical BiochemistryCellLeucovorinPromyelocytic Leukemia Proteinmedicine.disease_causeDeoxycytidineAntineoplastic Combined Chemotherapy Protocolsbiologyvirus diseasesNuclear ProteinsMiddle AgedOxaliplatinSurvival Ratemedicine.anatomical_structureImmunohistochemistryoxaliplatin/fluoropyrimidineFemaleFluorouracilColorectal Neoplasmsmedicine.drugAdultmedicine.medical_specialtyAntimetabolites AntineoplasticPML; oxaliplatin/fluoropyrimidine; colorectal cancerAntineoplastic Agentscolorectal cancerPromyelocytic leukemia proteinPredictive Value of TestsInternal medicinemedicineHumansCapecitabineAgedRetrospective StudiesPMLbusiness.industryTumor Suppressor ProteinsRetrospective cohort studyCell Biologymedicine.diseaseOxaliplatinApoptosisDrug Resistance Neoplasmbiology.proteinCarcinogenesisbusinessTranscription Factors
researchProduct

Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer.

2010

Nucleoside transporter proteins are specialized proteins that mediate the transport of nucleosides and nucleoside analog drugs across the plasma membrane. The human equilibrative nucleoside transporter 1 (hENT1) is a member of these proteins and mediates cellular entry of gemcitabine, cytarabine, and fludarabine. The hENT1 expression has been demonstrated to be related with prognosis and activity of gemcitabine-based therapy in breast, ampullary, lung, and pancreatic cancer. We investigated the immunohistochemical expression of hENT in tumor samples from 111 patients with resected gastric adenocarcinoma, correlating these data with clinical parameters and disease outcomes. None of the patie…

OncologyMaleSettore MED/06 - Oncologia MedicaPhysiologymedicine.medical_treatmentClinical BiochemistryNucleoside transporterEquilibrative nucleoside transporter 1Cohort StudiesMedicineNeoplasm MetastasisAged 80 and overbiologyMiddle AgedPrognosisImmunohistochemistryFludarabineSurvival RateDisease ProgressionFemalemedicine.drugAdultmedicine.medical_specialtyNucleoside transporterAntineoplastic AgentsAdenocarcinomaDisease-Free SurvivalEquilibrative Nucleoside Transporter 1Predictive Value of TestsStomach NeoplasmsPancreatic cancerInternal medicineBiomarkers TumorHumansSurvival rateAgedRetrospective Studiesbusiness.industryCancerCell Biologymedicine.diseaseGemcitabineRadiation therapyDrug Resistance NeoplasmGastric MucosaImmunologybiology.proteinNeoplasm Recurrence LocalbusinessJournal of cellular physiology
researchProduct

PML down-regulation in soft tissue sarcomas

2010

To date, little is known concerning the promyelocytic leukemia gene (PML) status in tumors of different origin, and its expression has never been evaluated in soft tissue sarcoma. The aim of the present study is focused on the identification of differences in terms of PML protein expression between different types of soft tissue sarcoma and the corresponding normal surrounding tissue. PML protein expression has been assessed by immunohistochemistry in six different histologic types of soft tissue sarcoma (synovial sarcoma, myofibroblastic sarcoma, angiosarcoma, liposarcoma, pleomorphic sarcoma, and leiomyosarcoma) and in the corresponding normal surrounding tissue. PML resulted significantl…

LeiomyosarcomaPathologymedicine.medical_specialtyPhysiologysoft tissue tumorSettore MED/06 - Oncologia MedicaClinical BiochemistryDown-RegulationLiposarcomaPromyelocytic Leukemia ProteinPleomorphic LiposarcomaPML sarcomasPromyelocytic leukemia proteinmedicineHumanssarcomasneoplasmsMyxoid liposarcomaPMLbiologybusiness.industrySoft tissue sarcomaTumor Suppressor ProteinsNuclear ProteinsSarcomaCell BiologyAnatomymedicine.diseaseImmunohistochemistrySynovial sarcomabody regionsbiology.proteinSarcomabusinessTranscription Factors
researchProduct

Response of GAFChromic® HD-V2 film dosimeter in 10-300 Gy dose range for radiation testing of electronic devices

2019

The study reported in this paper aimed to investigate the response of a GAFChromic? HD-V2 film dosimeter in the dose range between 10 and 300 Gy, normally used to perform irradiation tests on electronic devices with a 60Co gamma-ray irradiator. The well-defined linearity of response in terms of absorbance as a function of absorbed dose, easiness of handling and data analysis of irradiated dosimeters, reproducibility, stability, and insensitivity to visible light and most of the environmental parameters, make HD-V2 film a flexible, inexpensive and reliable dose measurement device. The study has shown a fogging effect of the dosimeter response since its value changes over time. Strategies and…

ReproducibilityRange (particle radiation)HD-V2 filmDosimeterMaterials scienceGafchromic dosimetryRadiation testingElectronic deviceNuclear Energy and EngineeringDoseGamma-ray irradiationAbsorbed doseCalibrationlcsh:QC770-798lcsh:Nuclear and particle physics. Atomic energy. RadioactivityIrradiationElectronicsSafety Risk Reliability and QualityBiomedical engineeringNuclear Technology and Radiation Protection
researchProduct

High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.

2008

Abstract Purpose. Several studies have suggested that KRAS somatic mutations may predict resistance to cetuximab- and panitumumab-based treatments in metastatic colorectal cancer (CRC) patients. Nevertheless, most experiences were conducted on samples from primaries. The aim of this study was to evaluate the grade of concordance in terms of KRAS status between primaries and related metastases. Patients and Methods. We analyzed KRAS codon 12 and 13 mutations from formalin-fixed sections of 107 CRC primaries and related metastases. Eight pairs were excluded from the analysis because of the low amount of tumor tissue in the available samples. The main characteristics were: 50 men, 49 women; me…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyColorectal cancerConcordancemedicine.disease_causeProto-Oncogene Proteins p21(ras)Proto-Oncogene ProteinsInternal medicinemedicineHumansPanitumumabNeoplasm MetastasisneoplasmsAgedRetrospective StudiesAged 80 and overCetuximabbusiness.industryRetrospective cohort studyMiddle Agedmedicine.diseasedigestive system diseasesConfidence intervalErbB ReceptorsClinical PracticeGenes rasOncologyMutationras ProteinsFemaleKRASKRAScolorectal tumorsColorectal Neoplasmsbusinessmedicine.drug
researchProduct

Human equilibrative nucleoside transporter 1 as a predictor of efficacy to gemcitabine in angiosarcoma and leiomyosarcoma.

2016

11062Background: Human equilibrative nucleoside transporter 1 (hENT1) is the major gemcitabine transporter into cells. Gemcitabine is an active drug in different sarcoma subtypes including leiomyos...

LeiomyosarcomaDrugCancer Researchbiologybusiness.industrymedia_common.quotation_subjectTransporterEquilibrative nucleoside transporter 1medicine.diseaseGemcitabineOncologybiology.proteinCancer researchMedicineAngiosarcomaSarcomabusinessmedicine.drugmedia_commonJournal of Clinical Oncology
researchProduct

Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients

2011

Background\ud Receptor activator of NFkB (RANK), its ligand (RANKL) and the decoy receptor of RANKL (osteoprotegerin, OPG) play a pivotal role in bone remodeling by regulating osteoclasts formation and activity. RANKL stimulates migration of RANK-expressing tumor cells in vitro, conversely inhibited by OPG.\ud \ud Materials and Methods\ud We examined mRNA expression levels of RANKL/RANK/OPG in a publicly available microarray dataset of 295 primary breast cancer patients. We next analyzed RANK expression by immunohistochemistry in an independent series of 93 primary breast cancer specimens and investigated a possible association with clinicopathological parameters, bone recurrence and surviv…

Anatomy and PhysiologyMicroarraysSettore MED/06 - Oncologia MedicaCancer TreatmentLigandsMetastasisBone remodelingMetastasisBasic Cancer ResearchBreast TumorsBone and Soft Tissue SarcomasNeoplasm MetastasisMusculoskeletal SystemOligonucleotide Array Sequence AnalysisMultidisciplinaryPredictive markerReceptor Activator of Nuclear Factor-kappa BQRBone metastasisMiddle AgedImmunohistochemistryGene Expression Regulation NeoplasticOncologyRANKLMedicineFemaleResearch Articlemusculoskeletal diseasesmedicine.medical_specialtyHistologyScienceBone NeoplasmsBreast NeoplasmsBiologyBreast cancerAntibody TherapySDG 3 - Good Health and Well-beingOsteoprotegerinInternal medicinemedicineHumansRNA MessengerBoneBiologyAgedBreast cancer bone metastasis RANK-RANKLRANK LigandOsteoprotegerinComputational BiologyCancers and NeoplasmsRANK Ligandmedicine.diseaseEndocrinologyCancer researchbiology.protein
researchProduct

Deregulation of dicer and mir-155 expression in liposarcoma

2015

Liposarcoma (LPS) is the most common soft tissue sarcoma. It has been demonstrated that mir-155 was the most overexpressed miRNA in well-differentiated LPS(WDLPS)/dedifferentiated LPS (DDLPS). The aim of this study is to evaluate the involvement of Dicer, Drosha and mir-155 in development of LPS and their possible role in stratification of different histological subtypes. Dicer, Drosha and mir-155 mRNA levels were analyzed in formalin-fixed paraffin-embedded specimens from patients diagnosed with 62 LPS and compared with samples of adipose tissues of healthy donors. The experimental data were obtained using qRT-PCR comparing Dicer, Drosha and mir-155 expression levels in tumor samples versu…

MaleRibonuclease IIIPathologymedicine.medical_specialtyDEAD-box RNA Helicases -- biosynthesis -- genetics -- metabolismSettore MED/06 - Oncologia MedicaMicroRNAs -- biosynthesis -- geneticsAdipose tissueLiposarcomaRibonuclease III -- biosynthesis -- genetics -- metabolismDroshamiR-155DEAD-box RNA Helicasemir-155DEAD-box RNA HelicasesRetrospective StudiemicroRNAmedicineHumansMicroarray AnalysiDroshaRetrospective StudiesbiologySoft tissue sarcomaAnatomical pathologyMicroRNALiposarcomaSciences bio-médicales et agricolesmedicine.diseaseMicroarray AnalysisLiposarcoma -- genetics -- metabolism -- pathologyDicer; Drosha; liposarcoma; mir-155; DEAD-box RNA Helicases; Female; Humans; Liposarcoma; Male; MicroRNAs; Microarray Analysis; Retrospective Studies; Ribonuclease IIIMicroRNAsOncologyliposarcomabiology.proteinlipids (amino acids peptides and proteins)FemaleClinical Research PaperDicerDicer; Drosha; Liposarcoma; Mir-155; DEAD-box RNA Helicases; Female; Humans; Liposarcoma; Male; MicroRNAs; Microarray Analysis; Retrospective Studies; Ribonuclease III; OncologyHumanDicer
researchProduct

Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients

2008

Background: Promyelocytic leukemia (PML) tumor suppressor gene plays a key role in acute PML pathogenesis but its involvement in pathogenesis and prognosis of solid cancers has not been defined yet. Patients and methods: In all, 62 ampullary adenocarcinoma patients who underwent curative surgery between 1996 and 2005 were included. Expression analysis of PML was carried out by immunohistochemical staining and correlated with disease-free survival (DFS) and overall survival (OS). Results: In 24 tumor specimens (38.7%), PML was classified as absent, in 16 (25.8%) as focally expressed and in 22 (35.5%) as diffusely expressed. By univariate analysis, DFS was significantly influenced by patholog…

AdultMaleOncologyAmpulla of Vatermedicine.medical_specialtyPathology(PML)ampullary cancerTumor suppressor geneCommon Bile Duct NeoplasmsAdenocarcinomaPromyelocytic Leukemia ProteinsurvivalCohort StudiesPathogenesispromyelocytic leukemia gene expressionPromyelocytic leukemia proteinampulla of vater cancer; promyelocytic leukemia gene expression; prognosisInternal medicineBiomarkers TumorHumansMedicinePathologicalAgedRetrospective StudiesAged 80 and overUnivariate analysisPMLbiologybusiness.industryTumor Suppressor ProteinsNuclear Proteinsampullary cancerHematologyMiddle AgedPrognosismedicine.diseaseSurvival AnalysisGene Expression Regulation NeoplasticLeukemiaOncologyPML; ampullary cancer; survivalbiology.proteinImmunohistochemistryT-stageampulla of vater cancerFemalebusinessTranscription FactorsAnnals of Oncology
researchProduct

Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study

2022

Abstract Aims The KWAY project aims to investigate the economic sustainability of the up-front NGS technologies adoption in the analysis of clinically relevant molecular alterations in NSCLC patients. Methods The diagnostic workflow and the related sustained costs of five Italian referral centers were assessed in four different evolving scenarios were analyzed. For each scenario, two alternative testing strategies were evaluated: the Maximized Standard strategy and the Maximized NGS strategy. Results For each center, the robustness of obtained results was verified through a deterministic sensitivity analysis, observing the variation of total costs based on a variation of ±20 % of the input …

Predictive molecular pathologyLung NeoplasmsTotal costCostCost; NGS; NSCLC; Predictive molecular pathology; Single-gene test; Algorithms; High-Throughput Nucleotide Sequencing; Humans; Italy; Multicenter Studies as Topic; Carcinoma Non-Small-Cell Lung; Lung NeoplasmsNSCLCRobustness (computer science)Carcinoma Non-Small-Cell LungCost evaluationMedicineHumansMulticenter Studies as TopicNon-Small-Cell LungMolecular pathologybusiness.industryCarcinomaHigh-Throughput Nucleotide SequencingHematologyReliability engineeringWorkflowOncologyEconomic sustainabilityItalyNGSSingle-gene testNon small cellbusinessAlgorithms
researchProduct

Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade

2007

Reelin is a glycoprotein that plays a critical role in the regulation of neuronal migration during brain development and, since reelin has a role in the control of cell migration, it might represents an important factor in cancer pathology. In this study, 66 surgical specimens of prostate cancer were analyzed for reelin expression by immunohistochemical method. The reelin expression was correlated with Gleason score and individual Gleason patterns. Reelin expression was found in 39% prostate cancers. Stromal tissues, normal epithelial cells and prostate intraepithelial neoplasia (PIN) of any grade around and distant from cancer were always negative for reelin. Reelin was found in malignant …

MalePathologymedicine.medical_specialtyStromal cellCell Adhesion Molecules NeuronalNerve Tissue Proteinsurologic and male genital diseasesGleason Score 6Pathology and Forensic MedicineProstate cancerProstatereelinBiomarkers TumorcancerMedicineHumansReelinGleason scoreneoplasmsAgedAged 80 and overIntraepithelial neoplasiaExtracellular Matrix Proteinsprostatebiologybusiness.industrySerine EndopeptidasesCancerProstatic NeoplasmsMiddle Agedmedicine.diseaseImmunohistochemistryReelin Proteinsurgical procedures operativemedicine.anatomical_structurenervous systembiology.proteinImmunohistochemistrybusiness
researchProduct

Dicer and drosha expression and response to bevacizumab-based therapy in advanced colorectal cancer patients.

2013

PURPOSE: The miRNA-regulating enzymes Dicer and Drosha exhibit aberrant expression in several cancer types. Dicer and Drosha play a crucial role during the angiogenetic process in vitro and, for Dicer, in vivo. We aimed to investigate the potential role of Dicer and Drosha in predicting response to Bevacizumab-based therapy in advanced colorectal cancer (CRC) patients. METHODS: Dicer and Drosha mRNA levels were analysed in formalin-fixed paraffin-embedded specimens from patients affected by advanced CRC treated with or without Bevacizumab-containing regimens (n=116 and n=50, respectively) and from patients with diverticulosis as control group (n=20). The experimental data were obtained usin…

MaleRibonuclease IIICancer ResearchSettore MED/06 - Oncologia Medicagenetic processesAngiogenesis InhibitorsKaplan-Meier EstimateDEAD-box RNA HelicasesangiogenesisIntestinal MucosaOligonucleotide Array Sequence AnalysisAged 80 and overReverse Transcriptase Polymerase Chain Reactionfood and beveragesMiddle AgedPrognosisImmunohistochemistryCRCBevacizumabGene Expression Regulation NeoplasticqPCRTreatment OutcomeOncologyMonoclonalImmunohistochemistryFemaleColorectal Neoplasmsmedicine.drugAdultBevacizumabBiologyAntibodies Monoclonal HumanizedDroshaYoung AdultSDG 3 - Good Health and Well-beingmicroRNAmedicineHumansDroshamiRNAAgedGene Expression ProfilingfungiCancermedicine.diseaseGene expression profilingenzymes and coenzymes (carbohydrates)miRNA; angiogenesisMultivariate AnalysisCancer researchbiology.proteinBevacizumab; CRC; Dicer; Drosha; miRNAs; qPCRDicerDicer
researchProduct

Changes in surgicaL behaviOrs dUring the CoviD-19 pandemic. The SICE CLOUD19 Study

2021

Abstract Background The spread of the SARS-CoV2 virus, which causes COVID-19 disease, profoundly impacted the surgical community. Recommendations have been published to manage patients needing surgery during the COVID-19 pandemic. This survey, under the aegis of the Italian Society of Endoscopic Surgery, aims to analyze how Italian surgeons have changed their practice during the pandemic. Methods The authors designed an online survey that was circulated for completion to the Italian departments of general surgery registered in the Italian Ministry of Health database in December 2020. Questions were divided into three sections: hospital organization, screening policies, and safety profile of…

Laparoscopic surgerySettore MED/18 - CHIRURGIA GENERALEmedicine.medical_treatmentlaparoscopyCOVID-19; Elective surgery; Emergency surgery; Laparoscopic surgery; SurveyOral HealthLaparoscopic surgerycross infection (MeSH)COVID-19; Elective surgery; Emergency surgery; Laparoscopic surgery; Survey.Surveys and QuestionnairesEpidemiologyPandemicInfection controlPractice Patterns Physicians'emergency surgeryLaparoscopySurveyhumansmedicine.diagnostic_testGeneral Commentarylaparoscopic surgeryinfection controlItalyEmergency surgeryphysicians'Original ArticleElective Surgical ProcedureHumanheating ventilation air conditioningmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)fallow periodelective surgical procedurespandemicsNOaerosol generating proceduresSurvey.COVID-19; elective surgery; emergency surgery; laparoscopic surgery; survey; COVID-19; elective surgical procedures; humans; infection control; Italy; laparoscopy; pandemics; practice patterns physicians'; SARS-CoV-2; surveys and questionnairesmedicinesurveyElective surgeryElective surgeryInfection ControlElective Surgical ProcedurePandemicbusiness.industrySARS-CoV-2General surgerySurvey; Laparoscopic surgery; COVID-19; Elective surgery; Emergency surgeryCOVID-19practice patternsSurgeryelective surgerysurveys and questionnairesLaparoscopySurgerybusiness
researchProduct

Telemedicine during Covid-19 pandemic: Advantage or critical issue?

2020

Telemedicine offers a support to traditional medicine, delivering clinical services when distance is a critical factor. Although this tool does not replace a medical examination, during Covid-19 pandemic, it reduces the spread of infection and avoids the need for a patient’s visit. It is useful in the management of chronic disorders or for patients undergoing palliative treatment. The University Hospital of Palermo has applied this in cases of chronic illness caring for patients who cannot stop their treatment, such as Department of Onco-Haematology, Internal Medicine, Dermatology, etc. The Department of Legal Medicine of Palermo, in particular, is also using telemedicine to manage medico-…

medicine.medical_specialtyTelemedicinePalliative careCoronavirus disease 2019 (COVID-19)Pneumonia ViralHealth Services AccessibilityPublic health serviceBetacoronavirus03 medical and health sciences0302 clinical medicineSettore MED/43 - Medicina LegalePandemicHumansMedicine030216 legal & forensic medicine030212 general & internal medicineDisease management (health)PandemicsSARS-CoV-2business.industryCommunicationPalliative CareMedical jurisprudenceCOVID-19Disease ManagementGeneral Medicinemedicine.diseaseTelemedicineTelemedicine covid 19 clinical servicesOutpatient visitsItalyChronic DiseaseMedical emergencyCoronavirus InfectionsbusinessMedico-Legal Journal
researchProduct

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial

2015

Background: Evidence suggests that metastatic colorectal carcinoma (mCRC) has a high level of intratumor heterogeneity. We carried out a quantitative assessment of tumor heterogeneity for KRAS, NRAS, BRAF and PIK3CA mutations, in order to assess potential clinical implications. Patients and methods: Tumor samples (n = 182) from the CAPRI-GOIM trial of first-line cetuximab + FOLFIRI in KRAS exon-2 wild-type mCRC patients were assessed by next-generation sequencing that allows quantitative assessment of mutant genes. Mutant allelic frequency was normalized for the neoplastic cell content and, assuming that somatic mutations usually affect one allele, the Heterogeneity Score (HS) was calculate…

OncologyNeuroblastoma RAS viral oncogene homologOrganoplatinum CompoundsColorectal cancerSettore MED/06 - Oncologia MedicaLeucovorinCetuximabCetuximab; Colorectal cancer; Mutations; Next-generation sequencing; Tumor heterogeneity; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Resistance Neoplasm; Fluorouracil; GTP Phosphohydrolases; Gene Frequency; High-Throughput Nucleotide Sequencing; Humans; Leucovorin; Membrane Proteins; Mutation; Organoplatinum Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Treatment Outcome; Hematology; OncologyColorectal Neoplasmmedicine.disease_causeGTP PhosphohydrolasesGTP PhosphohydrolasePhosphatidylinositol 3-KinasesGene FrequencyAntineoplastic Combined Chemotherapy ProtocolsMembrane ProteinClass I Phosphatidylinositol 3-KinasecolorectalCetuximabHigh-Throughput Nucleotide SequencingHematologyTreatment OutcomeOncologyFOLFIRIKRASFluorouracilColorectal Neoplasmsmedicine.drugHumanProto-Oncogene Proteins B-rafmedicine.medical_specialtyTumor heterogeneityClass I Phosphatidylinositol 3-KinasesProto-Oncogene Proteins p21(ras)Internal medicinemedicinecancerHumansneoplasmsAllele frequencyAntineoplastic Combined Chemotherapy ProtocolSettore MED/08 - ANATOMIA PATOLOGICAbusiness.industryCarcinomaOrganoplatinum CompoundMembrane ProteinsCancermedicine.diseaseColorectal cancerdigestive system diseasesDrug Resistance NeoplasmMutationCancer researchNext-generation sequencingNeoplastic cellCamptothecinPhosphatidylinositol 3-Kinasebusiness
researchProduct

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients

2015

// Bruno Vincenzi 1 , Chiara Cremolini 2 , Andrea Sartore-Bianchi 3 , Antonio Russo 4 , Francesco Mannavola 5 , Giuseppe Perrone 6 , Francesco Pantano 1 , Fotios Loupakis 2 , Daniele Rossini 2 , Elena Ongaro 7 , Erica Bonazzina 3 , Emanuela Dell’Aquila 1 , Marco Imperatori 1 , Alice Zoccoli 1 , Giuseppe Bronte 4 , Giovanna De Maglio 7 , Gabriella Fontanini 8 , Clara Natoli 9 , Alfredo Falcone 2 , Daniele Santini 1 , Andrea Onetti-Muda 6 , Salvatore Siena 3 , Giuseppe Tonini 1 and Giuseppe Aprile 7 1 Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy 2 Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy 3 Niguarda Cancer Center, Osped…

MalePathologyColorectal cancerSettore MED/06 - Oncologia MedicaColorectal NeoplasmRetrospective StudieAntineoplastic Combined Chemotherapy ProtocolsTumor Cells Culturededucation.field_of_studyUnivariate analysisBevacizumab; Colorectal cancer; K-Ras; Mutation rate; Prognosis; OncologyLiver NeoplasmsMiddle AgedPrognosisBevacizumabSurvival RateOncologyLiver NeoplasmCohortFemaleK-Ras; mutation rate; colorectal cancer; bevacizumab; prognosisColorectal NeoplasmsK-RasResearch Papermedicine.drugHumanmedicine.medical_specialtyBevacizumabPrognosiMutation ratePopulationBevacizumab; Colorectal cancer; K-Ras; Mutation rate; Prognosis; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins p21(ras); Real-Time Polymerase Chain Reaction; Retrospective Studies; Survival Rate; Tumor Cells Cultured; OncologyReal-Time Polymerase Chain ReactionFollow-Up StudieProto-Oncogene Proteins p21(ras)Internal medicinemedicineHumanseducationSurvival rateRetrospective StudiesNeoplasm StagingAntineoplastic Combined Chemotherapy Protocolbusiness.industryCancerRetrospective cohort studymedicine.diseaseColorectal cancerK-RaMutationbusinessFollow-Up Studies
researchProduct

Performance of the Glass Block in Photovoltaic Generation

2015

In this article is presented the preliminary evaluation of the performance of radiation transmission of glass block, used in support of photovoltaic cells, investigating different internal surface points of the block, which are subject to different shading during daylight hours. The aim is to establish how the edging setting, the only opaque element, can reduce the amount of light radiation during the day, introducing in this way a reduction of efficiency of the entire generation system. The generation system can be based on traditional photovoltaic cells or on the most suitable dye sensitized solar cells. An experimental measurement setup employing a microprocessor-based instrument has bee…

EngineeringOpacitybusiness.industryPhotovoltaic systemfungiElectrical engineeringintegrated photovoltaic DSSCSettore ICAR/10 - Architettura TecnicaSettore ING-IND/32 - Convertitori Macchine E Azionamenti ElettriciRenewable energySettore ING-IND/33 - Sistemi Elettrici Per L'EnergiaDye-sensitized solar cellSettore ING-IND/31 - Elettrotecnicagreen energyTransmission (telecommunications)integrated photovoltaicElectronic engineeringDaylightShadingDSSCbusinessBlock (data storage)
researchProduct

Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases.

2011

Receptor activator of NFκB ligand (RANKL), RANK, and osteoprotegerin (OPG) represent the key regulators of bone metabolism both in normal and pathological conditions, including bone metastases. To our knowledge, no previous studies investigated and compared RANK expression in primary tumors and in bone metastases from the same patient. We retrospectively examined RANK expression by immunohistochemistry in 74 bone metastases tissues from solid tumors, mostly breast, colorectal, renal, lung, and prostate cancer. For 40 cases, tissue from the corresponding primary tumor was also analyzed. Sixty-six (89%) of the 74 bone metastases were RANK-positive and, among these, 40 (59.5%) showed more than…

medicine.medical_specialtySettore MED/06 - Oncologia MedicaPhysiologyClinical Biochemistrycolorectal cancerBone NeoplasmsBone remodelingMetastasisProstate cancerbreast cancerOsteoprotegerinInternal medicinemedicineHumansbone metastasibiologyReceptor Activator of Nuclear Factor-kappa Bbusiness.industryMedicine (all)Bone metastasisCell Biologymedicine.diseasePrimary tumorbone metastasis; breast cancer; colorectal cancerImmunohistochemistryEndocrinologyBone Neoplasms; Humans; Immunohistochemistry; Receptor Activator of Nuclear Factor-kappa B; Medicine (all); Physiology; Clinical Biochemistry; Cell BiologyRANKLCancer researchbiology.proteinImmunohistochemistrybusinessJournal of cellular physiology
researchProduct

Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma

2017

Background: The expression of human equilibrative nucleoside transporter 1 (hENT1), the major gemcitabine transporter into cells, has been thoroughly investigated as a predictive marker of response to gemcitabine in pancreatic cancer and biliary tract cancers. Since gemcitabine is widely used in the treatment of leiomyosarcoma and angiosarcoma, we investigated the correlation between hENT1 expression and gemcitabine efficacy in these sarcoma subtypes.Methods: We retrospectively identified 71 patients affected by advanced angiosarcoma (26) or leiomyosarcoma (45) treated within five Italian referral centres for sarcoma; among them, 49 patients (15 angiosarcoma, 34 leiomyosarcoma) were treated…

0301 basic medicineOncologyLeiomyosarcomaMalePathologyCancer ResearchGene ExpressionKaplan-Meier EstimateEquilibrative nucleoside transporter 1Deoxycytidine0302 clinical medicineRetrospective StudieMedicineAngiosarcomaAged 80 and overPredictive markerbiologygemcitabineMiddle AgedSurvival RateOncology030220 oncology & carcinogenesishuman equilibrative nucleoside transporter 1; gemcitabine; leiomyosarcoma; angiosarcomaFemaleSarcomamedicine.drugHumanLeiomyosarcomaAdultmedicine.medical_specialtyAntimetabolites AntineoplasticHemangiosarcomahuman equilibrative nucleoside transporter 1; gemcitabine; leiomyosarcoma; angiosarcoma; Adult; Aged; Aged 80 and over; Antimetabolites Antineoplastic; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Gene Expression; Hemangiosarcoma; Humans; Kaplan-Meier Estimate; Leiomyosarcoma; Male; Middle Aged; Retrospective Studies; Survival Rate; Oncology; Cancer ResearchDisease-Free Survivalhuman equilibrative nucleoside transporter 1Equilibrative Nucleoside Transporter 103 medical and health sciencesInternal medicinePancreatic cancerHumansSurvival rateRetrospective StudiesAgedangiosarcomabusiness.industrymedicine.diseaseGemcitabine030104 developmental biologybiology.proteinTranslational Therapeuticsbusiness
researchProduct

The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients

2013

Tumour-associated Macrophages (TAM) present two different polarizations: classical (M1) characterized by immunostimulation activity and tumour suppression; alternative (M2) characterized by tumour promotion and immune suppression. In this retrospective study, we evaluated the correlation between the two forms of TAM with survival time in radically resected gastric cancer patients. A total of 52 chemo- and radio- naive patients were included. Two slides were prepared for each patient and double-stained for CD68/NOS2 (M1) or CD68/CD163 (M2) and five representative high-power fields per slide were evaluated for TAM count. The median value of the two macrophage populations density and the media…

Malemedicine.medical_specialtyPathologyMultivariate analysisSettore MED/06 - Oncologia MedicaKaplan-Meier EstimateGastroenterologyImmune systemM1 polarization; M2 polarization; gastric cancerGastrectomyStomach NeoplasmsInternal medicinemedicineHumanstumour associated macrophages M1 polarization M2 polarization prognostic factor gastric cancerRadical surgeryprognostic factorRetrospective Studiesbusiness.industryCD68MacrophagesM2 polarizationgastric cancerM1 polarizationCell PolarityCancerRetrospective cohort studyOriginal ArticlesCell BiologyMiddle AgedPrognosisM2 Macrophagemedicine.diseaseTreatment OutcomeMultivariate Analysistumour associated macrophagesMolecular MedicineFemalebusinessCD163Journal of Cellular and Molecular Medicine
researchProduct

A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

2019

No luminal; Subtipus intrínsec; Càncer de mama No luminal; Subtipo intrínseco; Cáncer de mama Non-luminal; Intrinsic subtype, Breast cancer Background: In hormone receptor-positive (HR+)/HER2-negative breast cancer, the HER2-enriched and Basal-like intrinsic subtypes are associated with poor outcome, low response to anti-estrogen therapy and high response to chemotherapy. To date, no validated biomarker exists to identify both molecular entities other than gene expression. Methods: PAM50 subtyping and immunohistochemical data were obtained from 8 independent studies of 1,416 HR+/HER2-negative early breast tumors. A non-luminal disease score (NOLUS) from 0 to 100, based on percentage of estr…

0301 basic medicineCancer Researchmedicine.medical_specialtyintrinsic subtype:Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES]:Genetic Phenomena::Gene Expression Regulation::Gene Expression Regulation Neoplastic [PHENOMENA AND PROCESSES]medicine.medical_treatmentEstrogen receptor:fenómenos genéticos::regulación de la expresión génica::regulación de la expresión génica neoplásica [FENÓMENOS Y PROCESOS]:aminoácidos péptidos y proteínas::proteínas::receptores citoplásmicos y nucleares::receptores de esteroides::receptores de estrógenos [COMPUESTOS QUÍMICOS Y DROGAS]lcsh:RC254-282Gastroenterology03 medical and health sciencesbreast cancer0302 clinical medicineBreast cancerMama - CàncerInternal medicineRegulació genèticaProgesterone receptorMedicinePAM50Original Research:neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES]Chemotherapynon-luminalbusiness.industry:Amino Acids Peptides and Proteins::Proteins::Receptors Cytoplasmic and Nuclear::Receptors Steroid::Receptors Estrogen [CHEMICALS AND DRUGS]lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyEstrògens - ReceptorsOncologyHormone receptor030220 oncology & carcinogenesisCohortgene expressionBiomarker (medicine)ImmunohistochemistrybusinessFrontiers in Oncology
researchProduct